XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net loss $ (398,509) $ (70,253)
Adjustments to reconcile net loss to net cash used in operating activities:    
Goodwill Impairment 330,309  
Depreciation and amortization expense 7,242 6,598
Provisions for credit losses 199 (200)
Amortization of deferred contract acquisition costs 476 391
Amortization of deferred contract fulfillment costs 107 133
Noncash compensation costs incurred by selling shareholders   2,025
Stock-based compensation expense 21,008 12,075
Loss on equity method investment 652 211
Deferred income taxes (13) (443)
Changes in operating assets and liabilities, net of acquisition:    
Accounts receivable 2,340 4,290
Inventories 299 (495)
Deferred contract acquisition costs (793) (501)
Prepaid expenses and other current assets 4,198 (1,838)
Other assets (210) (169)
Accounts payable (247) (4,601)
Accrued expenses and other current liabilities (14,159) (8,446)
Other long-term liabilities   (16)
Deferred revenue 17,953 (952)
Net cash used in operating activities (29,148) (62,191)
Cash flows from investing activities:    
Purchases of property and equipment (18) (68)
Capitalized software development costs (6,751)  
Investment in less than majority owned joint venture (980)  
Purchases of investments (389,990) (499,223)
Net cash used in investing activities (397,739) (499,291)
Cash flows from financing activities:    
Proceeds from exercise of common stock options 289 2,536
Proceeds from employee stock purchase plan 1,268 1,501
Payments for the purchase of treasury stock (1)  
Payment of contingent consideration   (11,790)
Net cash provided by (used in) financing activities 1,556 (7,753)
Effect of exchange rates changes on cash, cash equivalents, and restricted cash (328) (247)
Net decrease in cash, cash equivalents, and restricted cash (425,659) (569,482)
Cash, cash equivalents, and restricted cash at beginning of period 539,341 747,211
Cash, cash equivalents, and restricted cash at end of period 113,682 177,729
Cash, cash equivalents, and restricted cash at end of period:    
Cash and cash equivalents 112,887 176,934
Restricted cash 795 795
Total cash, cash equivalents, and restricted cash at end of period 113,682 177,729
Supplemental disclosure of cash flow information:    
Cash paid (refunded) for income taxes $ 458 (454)
Supplemental disclosure of non-cash investing and financing activities:    
Issuance of common stock in settlement of earnout   4,298
Receivable related to exercise of common stock options   $ 4